Eyelash enhancement properties of topical dechloro ethylcloprostenolamide

Objective: To assess subjective reports by users of MD Lash Factor^TM that it improved the appearance of their eyelashes, especially in length. Methods: A randomized, double‐blind, clinical trial was performed on 34 healthy volunteers who were randomly assigned to one of three different treatment groups of varying concentrations of the key ingredient (dechloro ethylcloprostenolamide, a novel synthetic topical prostaglandin analogue) and a placebo group. Results: All treatment groups demonstrated a statistically significant increase in eyelash length after 4 weeks of daily use. Group A: 1.69?mm, Group B: 1.94?mm, Group D: 1.44?mm, and Group C (placebo): 0.63?mm. There were no complications. Fifteen patients reported minimal initial transient irritation. Conclusion: Subjective reports by users of improved appearance in their eyelashes were confirmed. Use of dechloro ethylcloprostenolamide had minimal side effects.